BrightGene Bio-Medical Technology Co

BrightGene Bio-Medical Technology Co CapEx/D&A

The CapEx to Depreciation Ratio of BrightGene Bio-Medical Technology Co (688166.SS) as of Nov 22, 2026 is 6.52. In the previous year, CapEx to Depreciation Ratio was 11.05 — a change of -40.94% (lower).

CapEx/D&A

6.52

YoY

-40.94%

Last updated:

CapEx to Depreciation Ratio of BrightGene Bio-Medical Technology Co is 2024 6.52 . CapEx to Depreciation Ratio of BrightGene Bio-Medical Technology Co was 2023 11.05 . It decreases by -40.94% lower compared to the previous year.

The BrightGene Bio-Medical Technology Co CapEx/D&A history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/D&A
Date
CapEx/D&A
Jan 1, 2017
5.98 CNY
Jan 1, 2018
7.07 CNY
Jan 1, 2019
5.33 CNY
Jan 1, 2020
19.74 CNY
Jan 1, 2021
39.21 CNY
Jan 1, 2022
20.70 CNY
Jan 1, 2023
11.05 CNY
Jan 1, 2024
6.52 CNY
The BrightGene Bio-Medical Technology Co CapEx/D&A history
YEARCapEx/D&AYoY
6.52-40.94%
11.05-46.62%
20.70-47.21%
39.21+98.64%
19.74+270.32%
5.33-24.66%
7.07+18.32%
5.98+104.30%
2.93—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BrightGene Bio-Medical Technology Co Stock analysis

What does BrightGene Bio-Medical Technology Co do? BrightGene Bio-Medical Technology Co., Ltd. generates revenue by researching, developing, and manufacturing biopharmaceuticals, medicines, and special generic active pharmaceutical ingredients and finished dosage forms. The company's product portfolio centers on antifungal, antiviral, and immunosuppressive APIs, alongside other APIs and preparations. Its generic drug offerings specifically include entecavir, caspofungin, micafungin, posaconazole, everolimus, and fondaparinux sodium. The firm sells these products to customers in both domestic and overseas markets. By leveraging its capabilities in producing essential active pharmaceutical ingredients and finished dosage forms, the company serves the broader pharmaceutical sector through its established manufacturing and research operations. BrightGene Bio-Medical Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BrightGene Bio-Medical Technology Co stock

CapEx to Depreciation Ratio of BrightGene Bio-Medical Technology Co is 6.52 in 2024.

CapEx to Depreciation Ratio of BrightGene Bio-Medical Technology Co changed from 11.05 to 6.52, representing a -40.94% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Depreciation Ratio BrightGene Bio-Medical Technology Co since 2006 – with annual values, charts, and detailed analysis.

The CapEx/D&A ratio compares investment spending to asset depreciation. Ratios above 1.0x indicate the company is growing its asset base, below 1.0x suggests underinvestment.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Depreciation Ratio's BrightGene Bio-Medical Technology Co with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Depreciation Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Depreciation Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — BrightGene Bio-Medical Technology Co

All Key Metrics — BrightGene Bio-Medical Technology Co